The NLPR3 inflammasome is an attractive drug target because NLRP3 inflammasome activation is associated not only with rare autoinflammatory disorders such as CINCA syndrome but also with the pathogenesis of various chronic inflammatory conditions (115). This evidence concerns the gene NLRP3 and CINCA syndrome.